blog navigation

blog posts

  • Cancer drug starts clinical trials in human brain-cancer patients

    U. of I. veterinary oncologist Dr. Timothy Fan, left, chemistry professor Paul Hergenrother and their colleagues are testing the safety of a new cancer drug in a clinical trial for humans with late-stage brain cancer. The compound has worked well in canine patients with brain cancer, lymphoma and osteosarcoma.

    U. of I. veterinary oncologist Dr. Timothy Fan, left, chemistry professor Paul Hergenrother and their colleagues are testing the safety of a new cancer drug in a clinical trial for humans with late-stage brain cancer. The compound has worked well in canine patients with brain cancer, lymphoma and osteosarcoma.

    Photo by L. Brian Stauffer

    Images

blog posts

  • Editor’s notes:
    To reach Paul Hergenrother, call 217-333-0363; email hergenro@illinois.edu.
    To reach Dr. Timothy Fan, call 217-333-5375; email t-fan@illinois.edu.
    The paper “Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients” is available online and from the U. of I. News Bureau.
    DOI: 10.18632/oncotarget.19085